An in vivo model to assess factors that may stimulate the generation of an immune reaction to erythropoietin

International Immunopharmacology

Volumn 6, Issue 4, 2006, Pages 647-655

  Ryan, Mary H ^a,b   Heavner, George A ^b   Brigham Burke, Michael ^b   McMahon, Frank ^a   Shanahan, Mary F ^a   Gunturi, Srinivas R ^c   Sharma, Basant ^d   Farrell, Francis X ^a,b  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^b CENTOCOR INC   (United States)

^c Pharmaceutical Sciences   (United States)

^d Global Biologics Supply Chain LLC   (United States)

Author keywords

Adjuvant; Animal model; Antibodies; Erythropoietin; PRCA

Indexed keywords

ERYTHROPOIETIN; ERYTHROPOIETIN ANTIBODY; FREUND ADJUVANT; IMMUNOLOGICAL ADJUVANT; OVALBUMIN; RECOMBINANT ERYTHROPOIETIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DETECTION; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN ANTIBODY REACTION; ANTIGEN RECOGNITION; ARTICLE; CHICKEN; CONCENTRATION RESPONSE; CONTROLLED STUDY; EXPERIMENTAL MODEL; HEMATOCRIT; IMMUNE RESPONSE; IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; IMMUNOSTIMULATION; IN VIVO STUDY; LEACHING; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SYRINGE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; DRUG PACKAGING; ENZYME-LINKED IMMUNOSORBENT ASSAY; ERYTHROPOIETIN, RECOMBINANT; HUMANS; MALE; MICE; MODELS, IMMUNOLOGICAL; OVALBUMIN; RED-CELL APLASIA, PURE; SYRINGES;

EID: 33644546683     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2005.10.001     Document Type: Article

References (20)

1. H. Schellekens Bioequivalence and the immunogenicity of biopharmaceuticals Nat Rev Drug Disc 1 2002 457 462
2. J.L. Bussiere Animal models as indicators of immunogenicity of therapeutic proteins in humans F. Brown A.R. Mire-Sluis Immunogenicity of therapeutic biological products 2003 Karger Basel 135 139
3. J.-C. Ryff, and H. Schellekens Immunogenicity of rDNA-derived pharmaceuticals Trends Pharm Sci 23 2002 254 256
4. B. Sharma, F. Bader, T. Templeman, P. Lisi, M. Ryan, and G.A. Heavner Technical investigations into the cause of the increased incidence of antibody-mediated pure red cell aplasia associated with EPREX® Eur J Hosp Pharm 5 2004 86 91
5. A.K. Abbas, and A.H. Lichtman Cellular and molecular immunology 2003 Saunders Philadelphia
6. S.T. Larsen, G.D. Nielsen, and P. Thygesen Investigation of the adjuvant effect of polyethylene glycol (PEG) 400 in BALB/c mice Int J Pharm 231 2002 51 55
7. S.K. Clausen, S. Sobhani, O.M. Poulsen, L.K. Poulsen, and G.D. Nielsen Study of adjuvant effect of model surfactants from the groups of alkyl sulfates, alkylbenzene sulfonates, alcohol ethoxylates and soaps Food Chem Toxicol 38 2000 1065 1074
8. R.D. Lange, T.P. McDonald, and T. Jordan Antisera to erythropoietin: partial characterization of two different antibodies J Lab Clin Med 73 1969 78 90
9. E. Rioux, and A.J. Erley Immunologic studies of a partially purified sheep erythropoietin J Immunol 101 1968 6 11
10. M. Goto, A. Murakami, K. Akai, G. Kawanishi, M. Ueda, and H. Chiba Characterization and use of monoclonal antibodies directed against human erythropoietin that recognize different antigenic determinants Blood 74 1989 1415 1423
11. A.J. Sytkowski, and J.W. Fisher Isolation and characterization of an anti-peptide monoclonal antibody to human erythropoietin J Biol Chem 260 1985 14727 14731
12. D. Wen, J.-P.R. Boissel, T.E. Tracy, R.H. Gruninger, L.S. Mulcahy, and J. Czelusniak Erythropoietin structure-function relationships: high degree of sequence homology among mammals Blood 82 1993 1507 1516
13. G.L. Semenza, S.T. Koury, M.K. Nejfelt, J.D. Gearhart, and S.E. Antonarakis Cell-type-specific and hypoxia-inducible expression of the human erythropoietin gene in transgenic mice Proc Natl Acad Sci 88 1991 8725 8729
14. A. Braun, L. Kwee, M.A. Labow, and J. Alsenz Protein aggregates seem to play a key role among the parameters influencing the antigenicity of interferon alpha (IFN-α) in normal and transgenic mice Pharm Res 14 1997 1472 1478
15. M. De Serres, B. Ellis, J.E. Dillberger, S.K. Rudolph, J.T. Hutchins, and C.M. Boytos Immunogenicity of thrombopoietin mimetic peptide GW395058 in BALB/c mice and New Zealand white rabbits: evaluation of the potential for thrombopoietin neutralizing antibody in man Stem Cells 17 1999 203 209
16. S. Hermeling, H. Schellekens, D.J.A. Crommelin, and W. Jiskoot Micelle-associated protein in epoetin formulations: a risk factor for immunogenicity? Pharm Res 20 2003 1903 1907
17. A.P. Villalobos, S.R. Gunturi, and G.A. Heavner Interaction of polysorbate 80 with erythropoietin-a case study in protein-surfactant interactions Pharm Res 22 2005 1186 1194
18. K. Boven, J. Knight, F. Bader, J. Rossert, K.-U. Eckardt, and N. Casadevall Epoetin-associated pure red cell aplasia in patients with chronic kidney disease: solving the mystery Nephrol Dial Transplant 20 Suppl 3 2005 iii33 iii40
19. S. Mason, S. La, D. Mytych, S.J. Swanson, and J. Ferbas Validation of the BIAcore 3000 platform for detection of antibodies against erythropoietic agents in human serum samples Curr Med Res Opin 19 2003 651 659
20. R. Tacey, A. Greway, J. Smiell, D. Power, A. Kromminga, and M. Daha The detection of anti-erythropoietin antibodies in human serum and plasma: Part i. Validation of the protocol for a radioimmunoprecipitation assay J Immunol Methods 283 2003 317 329